PURE · Pure Bioscience, Inc.
$0.06
-0.02 (-22.50%)
At close · Sep 2
Going-concern doubt
— flagged Jun 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our history of recurring operating losses, and negative cash flows from operating activities give rise to substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Jun 15, 2026
Market Cap
$10.40M
Shares
130.02M
PURE metrics
57 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.06
Market cap
$10.40M
Price action
19 metricsPrice change (1W)
+33.3%
Price change (30D)
+33.3%
Price change (3M)
+14.3%
Price change (6M)
+33.3%
Price change (YTD)
+100.0%
Price change (1Y)
-11.1%
Trailing year
Price change (5Y)
-75.8%
52-week high
$0.11
52-week low
$0.04
Change from 52-week high
-27.3%
Change from 52-week low
+100.0%
Annualized volatility
151.0%
Beta
0.6
RSI (14D)
53.5
Price vs SMA 50
+16.2%
Price vs SMA 200
+25.8%
Avg volume (3M)
25,107
Relative volume
0.6
Average dollar volume
$1,719
Company
3 metricsSector
Consumer Defensive
Industry
Household & Personal Products
Shares outstanding
130.02M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
4.3×
reciprocal yield 23.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-21.2%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
58.9%
Operating margin
-79.2%
Trailing 12 months
Net margin
-91.2%
Gross profit (TTM)
$1.43M
Operating profit (TTM)
−$1.92M
Net income (TTM)
−$2.21M
Trailing 12 months
Diluted EPS (TTM)
$-0.01
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+3.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.42M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-0.9%
Year over year · fewer shares
Revenue CAGR (3Y)
+6.6%
Revenue CAGR (5Y)
-20.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-141.5%
Debt / equity
—
Current ratio
0.4
EBITDA (TTM)
−$3.04M
Free cash flow (TTM)
—
Quick ratio
0.4
Interest coverage
-4.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$983,000
Total assets
$1.56M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$1.78M
Capital expenditures (TTM)
—
R&D (TTM)
$312,000
SG&A (TTM)
$3.03M
Stock compensation (TTM)
$177,000
R&D / revenue
12.9%
Stock compensation / revenue
7.3%
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
23 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged